CNTY-101

Century Therapeutics' CNTY-101, an iPSC-derived CD19 CAR-iNK cell therapy, will be assessed in a Phase 1/2 trial for B-cell mediated autoimmune diseases.

Krystal Biotech reported a 473% increase in full-year revenue, driven by VYJUVEK sales, and anticipates European and Japanese regulatory decisions in 2025.

The follicular lymphoma treatment landscape is evolving, with over 55 therapies in development by more than 50 active pharmaceutical companies.

The NK cell therapy field is experiencing significant growth, driven by its potential to address unmet needs in cancer treatment with safer, more targeted options.